Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:COSNASDAQ:PMNNASDAQ:RENE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCOSCanadian Oil SandsC$0.00C$5.61▼C$13.87N/AN/A2.19 million shsN/APMNProMIS Neurosciences$1.96+0.5%$2.04$0.95▼$8.95$37.16M0.6737,761 shs654 shsRENECartesian Growth Co. II$11.21$11.11$10.52▼$11.92$242.36M-0.0162,761 shs14,898 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePMNProMIS Neurosciences0.00%-1.02%+0.52%-3.05%-71.28%RENECartesian Growth Co. II+0.09%+0.22%+0.90%+1.72%+6.56%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCOSCanadian Oil SandsN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences2.3094 of 5 stars3.54.00.00.01.11.70.6RENECartesian Growth Co. IIN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCOSCanadian Oil Sands3.00BuyC$0.52∞ UpsidePMNProMIS Neurosciences3.00Buy$8.00308.16% UpsideRENECartesian Growth Co. IIN/AN/AN/AN/ACurrent Analyst RatingsLatest PMN, COS, and RENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024COSCanadian Oil SandsFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$0.52(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCOSCanadian Oil SandsN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences$10K3,716.16N/AN/A$0.20 per share9.80RENECartesian Growth Co. IIN/AN/A$0.40 per share28.14($0.64) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCOSCanadian Oil SandsN/AN/A0.00N/AN/AN/AN/AN/AN/APMNProMIS Neurosciences-$13.21M-$1.13N/AN/AN/AN/AN/A-141.23%5/20/2024 (Estimated)RENECartesian Growth Co. II$11.44MN/A0.00∞N/AN/A-65.59%5.02%N/ALatest PMN, COS, and RENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PMNProMIS NeurosciencesN/A-$0.09-$0.09-$0.09N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCOSCanadian Oil SandsN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ARENECartesian Growth Co. IIN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCOSCanadian Oil SandsN/AN/AN/APMNProMIS NeurosciencesN/A1.461.46RENECartesian Growth Co. IIN/A0.220.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCOSCanadian Oil SandsN/APMNProMIS Neurosciences50.13%RENECartesian Growth Co. II58.96%Insider OwnershipCompanyInsider OwnershipCOSCanadian Oil SandsN/APMNProMIS Neurosciences10.30%RENECartesian Growth Co. II20.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCOSCanadian Oil Sands147,000N/AN/ANot OptionablePMNProMIS Neurosciences618.96 million17.01 millionNot OptionableRENECartesian Growth Co. IIN/A21.62 million17.30 millionNot OptionablePMN, COS, and RENE HeadlinesSourceHeadlineShort Interest in Cartesian Growth Co. II (NASDAQ:RENE) Increases By 312.5%marketbeat.com - April 25 at 10:22 PMWolverine Asset Management LLC Acquires 104,768 Shares of Cartesian Growth Co. II (NASDAQ:RENE)marketbeat.com - April 23 at 8:48 PMCartesian Growth Co. II (NASDAQ:RENE) Shares Up 0%americanbankingnews.com - April 19 at 2:58 AMCartesian Growth Co. II (NASDAQ:RENE) Short Interest Updatemarketbeat.com - March 28 at 8:23 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesThe Bottom is in For Tesla: Read This Before Buying the BounceApril 24, 2024 8:45 AMView The Bottom is in For Tesla: Read This Before Buying the BounceIs Estée Lauder on the Verge Of a Massive Comeback?April 4, 2024 11:10 AMView Is Estée Lauder on the Verge Of a Massive Comeback?DexCom Stock Gains from GLP-1 Diabetic UsersApril 2, 2024 7:16 AMView DexCom Stock Gains from GLP-1 Diabetic UsersInstitutions Think This Consumer Stock Could Break HigherApril 8, 2024 9:40 AMView Institutions Think This Consumer Stock Could Break HigherCostco vs. Walmart: Revenue Comparison of Two Retail GiantsApril 15, 2024 11:39 AMView Costco vs. Walmart: Revenue Comparison of Two Retail GiantsAll Headlines Company DescriptionsCanadian Oil SandsTSE:COSCanadian Oil Sands Limited is a Canada-based investment company. The Company owns a 36.74% interest in the Syncrude Joint Venture (Syncrude), a producer of low sulphur, light, synthetic crude oil (SCO). Syncrude is involved in the mining and upgrading of bitumen from oil sands near Fort McMurray in northern Alberta. The Syncrude Project is comprised of open-pit oil sands mines, utilities plants, bitumen extraction plants and an upgrading complex that processes bitumen into SCO. Syncrude's leases are located in the Athabasca oil sands deposit. Syncrude produces SCO by mining oil sands, extracting the bitumen from the sands, upgrading the recovered bitumen into lighter oil fractions and combining those fractions into a single SCO product.ProMIS NeurosciencesNASDAQ:PMNProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Cartesian Growth Co. IINASDAQ:RENECartesian Growth Corporation II does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses or entities. Cartesian Growth Corporation II was incorporated in 2021 and is based in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
